文献速递肝病

隐源性肝硬化的难题:缺乏治疗选择下的不良结局

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
PubMed 文献 · J Hepatol · 2018-08-23

本研究比较隐源性肝硬化与NASH相关肝硬化患者的结局。共纳入247例肝硬化患者,隐源性肝硬化103例,NASH肝硬化144例。中位随访29个月,隐源性肝硬化患者肝相关临床事件发生时间更短(12.0 vs 19.4个月),风险比为1.76(95%CI 1.02-3.06)。作者认为两者属同一疾病谱,隐源性肝硬化代表更晚期纤维化阶段。

要点

  • 隐源性肝硬化与NASH肝硬化患者年龄、性别、BMI、PNPLA3基因型及糖尿病患病率相似。
  • 隐源性肝硬化患者血清纤维化标志物更高,肝活检胶原含量及α-平滑肌肌动蛋白表达更多。
  • 隐源性肝硬化患者肝相关临床事件发生时间更短,风险比1.76(95%CI 1.02-3.06)。

核心结论

  • 隐源性肝硬化与NASH肝硬化人群 demographics 相似,但隐源性肝硬化纤维化更活跃且肝相关临床事件风险更高。
  • 作者认为两者属于同一疾病谱,隐源性肝硬化代表更晚期纤维化阶段。

研究设计与样本

  • 研究为队列研究,筛选适合临床试验的隐源性肝硬化或NASH肝硬化患者。
  • 肝活检显示肝脂肪变性<5%者( regardless of 其他组织学特征)定义为隐源性肝硬化。
  • 共纳入247例肝硬化患者(55.3±7.4岁,37%男性),其中NASH肝硬化144例,隐源性肝硬化103例。

主要发现

  • 中位随访29个月(IQR 21-33,最长45个月),20.6%患者发生肝相关临床事件。
  • 隐源性肝硬化患者肝相关临床事件平均发生时间显著短于NASH肝硬化患者(12.0 vs 19.4个月;p=0.001),风险比为1.76(95%CI 1.02-3.06)。
  • 隐源性肝硬化患者血清纤维化标志物更高,肝活检胶原含量及α-平滑肌肌动蛋白表达更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis and NASH-related cirrhosis from a cohort with longitudinal follow-up data. METHODS: Patients with cryptogenic cirrhosis or NASH cirrhosis were screened for a clinical trial. Patients with <5% hepatic steatosis regardless of other histologic features were considered to have cryptogenic cirrhosis. Clinico-laboratory data and adjudicated liver-related events (e.g. decompensation, qualification for transplantation, death) were available. RESULTS: A total of 247 patients with cirrhosis (55.3 ± 7.4 years, 37% male) were included; 144 had NASH cirrhosis and 103 had cryptogenic cirrhosis. During a median follow-up of 29 (IQR 21-33) months (max 45 months), 20.6% of patients had liver-related clinical events. Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05). However, patients with cryptogenic cirrhosis had higher serum fibrosis markers and greater collagen content and α-smooth muscle actin expression on liver biopsy. Compared to cirrhotic patients with NASH, patients with cryptogenic cirrhosis experienced significantly shorter mean time to liver-related clinical events (12.0 vs. 19.4 months; p = 0.001) with a hazard ratio of 1.76 (95% CI 1.02-3.06). CONCLUSIONS: Populations with NASH and cryptogenic cirrhosis have similar demographics, but patients with cryptogenic cirrhosis have evidence of more active fibrosis and a higher risk of liver-related clinical events. Thus, we believe these patients belong to the same spectrum of disease, with cryptogenic cirrhosis representing a more advanced stage of fibrosis. LAY SUMMARY: Significant liver damage and cirrhosis of the liver may develop without a known cause - a liver disease referred to as cryptogenic cirrhosis. In this work we found that, in the presence of metabolic abnormalities, cryptogenic cirrhosis may actually be a part of the non-alcoholic fatty liver disease spectrum. Yet, it appears to be more progressive than typical non-alcoholic fatty liver disease, leading to advanced liver disease at a faster rate.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi Z, Stepanova M, Sanyal AJ, et al. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol. 2018. PMID: 30144554. doi:10.1016/j.jhep.2018.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。